India's Zydus Life agrees $120 million settlement with Astellas over bladder drug

Feb 12 (Reuters) - India's Zydus Lifesciences and its U.S. unit will pay $120 million ‌to Astellas Pharma as part of ‌a deal to settle a patent dispute over the ​Japanese drugmaker's bladder disorder drug Mirabegron, the Indian firm said on Thursday. Zydus and its unit will also pay a pre-paid per‑unit licensing ‌fee on sales ⁠of its generic Mirabegron in the U.S. from the date of the ⁠agreement until September 2027, the company said. The deal will enable the company to continue ​marketing its ​generic ...